Pulse Biosciences names Jon Skinner as new CFO

MIAMI - Pulse Biosciences, Inc. (NASDAQ: NASDAQ:PLSE), a bioelectric medicine company focusing on its proprietary CellFX nanosecond Pulsed Field Ablation (nsPFA) technology, has announced the appointment of Jon Skinner as its new Chief Financial Officer, effective Monday. The leadership expansion is aimed at bolstering the company’s operational excellence and commercialization efforts for its CellFX nsPFA platform. According to InvestingPro, this appointment comes at a crucial time as the company seeks to strengthen its market position and operational capabilities.

Skinner brings a wealth of financial expertise to Pulse Biosciences, having held positions across the healthcare sector. His most recent role was as Vice President of FP&A and Investor Relations at Copeland, a private equity-backed industrial company. Previously, Skinner served as Vice President of Finance and Corporate Development at Imperative Care, a venture-backed medical technology company, where he was instrumental in M&A, strategy, partnerships, and sales operations. He also acted as interim CFO for Kandu Health during its spin-out and fundraising. Before that, Skinner held leadership roles at Teleflex (NYSE:TFX) and Axalta Coating Systems, contributing to significant transactions and the company’s IPO.

In his new role, Skinner is expected to leverage his strategic and financial insights to support the scaling of Pulse Biosciences’ commercialization and operational activities. Commenting on his appointment, Skinner expressed enthusiasm for joining the company at a pivotal time and his belief in the disruptive potential of the nanosecond PFA technology in treating various disease states. Subscribers to InvestingPro can access detailed financial analysis and additional ProTips to better understand the company’s market position and growth potential through comprehensive Pro Research Reports available for over 1,400 US stocks.

As part of his inducement to join the company, Skinner was granted options to purchase 300,000 shares of Pulse Biosciences’ common stock at $20.93 per share, the closing price on January 31, 2024. These options are set to vest over four years and are contingent upon the company achieving certain product revenue and market capitalization milestones.

Pulse Biosciences is committed to advancing bioelectric medicine with its CellFX nsPFA technology, which is designed to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively developing this technology for the treatment of atrial fibrillation and other markets with the potential for significant healthcare impact.

This announcement is based on a press release statement from Pulse Biosciences, Inc.

In other recent news, Axalta Coating Systems Ltd (NYSE:AXTA). reported remarkable fourth-quarter earnings, surpassing analyst expectations. The coatings company posted adjusted earnings per share of $0.60, exceeding the consensus estimate of $0.51. Revenue for the quarter was at $1.31 billion, aligning with analyst projections.

In addition, Axalta’s fourth-quarter net sales saw a 1% year-over-year increase to $1.3 billion. The company also reported a significant rise in net income by 85% to $137 million, yielding a net income margin of 10.5%. This is an improvement of 480 basis points from the same period in the previous year.

Furthermore, Axalta achieved a record fourth-quarter Adjusted EBITDA of $275 million, with the Adjusted EBITDA margin improving by 170 basis points year-over-year to 21.0%. The company’s net sales for the full year 2024 increased by 2% to $5.3 billion, with net income rising to $391 million, a significant improvement from $269 million in 2023.

Finally, the company projects full-year 2025 net sales to range from $5.35 billion to $5.4 billion and Adjusted EBITDA to range from $1.15 billion to $1.175 billion. These recent developments attest to Axalta’s resilient performance in a challenging macro environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.